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Abstract
Background: Nonvitamin	K	antagonist	oral	anticoagulants	(NOACs)	are	increasingly	
used	in	patients	with	atrial	fibrillation	(AF)	undergoing	elective	cardioversion	(ECV).	
The	aim	was	to	investigate	the	use	of	NOACs	and	warfarin	in	ECV	in	a	real-life	set-
ting	and	to	assess	how	the	chosen	regimen	affected	the	delay	to	ECV	and	rate	of	
complications.
Methods: Consecutive	AF	patients	undergoing	ECVs	in	the	city	hospitals	of	Helsinki	
between January 2015 and December 2016 were studied. Data on patient character-
istics,	delays	to	cardioversion,	anticoagulation	treatment,	acute	(<30	days)	complica-
tions,	and	regimen	changes	within	one	year	were	evaluated.
Results: Nine	hundred	patients	(59.2%	men;	mean	age,	68.0	±	10.0)	underwent	992	
ECVs,	of	which	596	 (60.0%)	were	performed	using	NOACs	and	396	 (40.0%)	using	
warfarin.	The	mean	CHA2DS2-VASc	 score	was	2.5	 (±1.6).	 In	patients	without	pre-
vious	 anticoagulation	 treatment,	 NOACs	 were	 associated	 with	 a	 shorter	 mean	
time	to	cardioversion	than	warfarin	(51	versus.	68	days,	respectively;	p	<	.001).	Six	
thromboembolic	events	 (0.6%)	occurred:	4	 (0.7%)	 in	NOAC-treated	patients	and	2	
(0.5%)	 in	warfarin-treated	patients.	Clinically	 relevant	bleeding	events	occurred	 in	
seven	patients	(1.8%)	receiving	warfarin	and	three	patients	(0.5%)	receiving	NOACs.	
Anticoagulation	treatment	was	altered	for	99	patients	(11.0%)	during	the	study	pe-
riod,	with	the	majority	(88.2%)	of	changes	from	warfarin	to	NOACs.
Conclusions: In	this	real-life	study,	the	rates	of	thromboembolic	and	bleeding	com-
plications	were	low	in	AF	patients	undergoing	ECV.	Patients	receiving	NOAC	therapy	
had a shorter time to cardioversion and continued their anticoagulation therapy more 
often than patients on warfarin.
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1  | INTRODUC TION
Atrial	fibrillation	(AF)	is	the	most	common	type	of	cardiac	arrhyth-
mia	(Kirchhof	et	al.,	2016).	Electrical	elective	cardioversion	(ECV)	is	
an	effective	way	to	restore	sinus	rhythm.	However,	cardioversion	is	
associated with an increased risk for thromboembolic events such as 
ischemic stroke and systemic embolism. Without preceding antico-
agulation,	there	is	a	5%–7%	risk	of	thromboembolism	(Arnold,	Mick,	
Mazurek,	Loop,	&	Trohman,	1992),	and	with	adequate	anticoagula-
tion	 therapy,	 the	 risk	 is	 reduced	 to	0.5%–1.6%	 (Klein	et	al.,	2001).	
According	to	the	current	AF	guidelines,	adequate	oral	anticoagula-
tion is recommended for at least 3 weeks before and for a minimum 
of	4	weeks	after	ECV	in	patients	with	AF	>	48	hr	or	of	unknown	du-
ration,	regardless	of	their	stroke	risk	profiles	(Kirchhof	et	al.,	2016).
Nonvitamin	K	 antagonists	 (NOACs)	have	been	 shown	 to	be	 as	
safe	and	effective	as	vitamin	K	antagonists	(VKAs)	in	the	setting	of	
cardioversion	(Cappato	et	al.,	2014;	Flaker	et	al.,	2014;	Nagarakanti	
et	al.,	2011).	Accordingly,	many	newly	diagnosed	AF	patients	 initi-
ate	 NOAC	 treatment	 (Forslund,	 Wettermark,	 &	 Hjemdahl,	 2016;	
Huisman	et	al.,	2015).	Due	to	their	rapid	onset	of	action,	their	pre-
dictable pharmacokinetics and pharmacodynamics and their ability 
to	 be	 used	 at	 fixed	 doses	 without	 routine	 laboratory	 monitoring,	
NOACs	 offer	 potential	 advantages	 over	 VKAs	 and	 may	 shorten	
the	waiting	times	for	elective	cardioversions	(Cappato	et	al.,	2014;	
Ezekowitz	et	al.,	2018;	Goette	et	al.,	2016).	At	the	beginning	of	war-
farin	therapy,	a	labile	international	normalized	ratio	(INR)	is	common,	
which	may	prolong	 the	 time	until	 ECV	can	be	performed	 (Ryman,	
Frick,	 Frykman,	&	Rosenqvist,	 2003).	As	 an	 alternative	 to	 prepro-
cedural	anticoagulation,	transesophageal	echocardiography	(TOE)	is	
useful	to	exclude	cardiac	thrombus	to	facilitate	early	cardioversion	
(Kirchhof	et	al.,	2016).
Earlier	studies	have	shown	that	one	 in	 three	new	NOAC	users	
switches	 from	 VKAs	 (Beyer-Westendorf	 et	 al.,	 2015;	 Forslund	
et	al.,	2016;	Gorst-Rasmussen	et	al.,	2015).	Moreover,	one	in	five	pa-
tients	discontinues	NOAC	treatment	within	the	first	year	(Forslund	
et	al.,	2016;	Gorst-Rasmussen	et	al.,	2015).	Understanding	the	rea-
sons	 for	 the	 changes	between	NOACs	 and	VKAs	 and	 for	 the	dis-
continuation of anticoagulation is essential to ensure treatment 
adherence	and	to	minimize	the	risk	of	potential	bleeding	and	throm-
boembolic events.
The aim of this study was to investigate the reasons for the de-
lays	in	ECV,	the	frequency	of	switching	anticoagulants,	and	the	rates	
of	 thromboembolic	 and	 bleeding	 events	 after	 cardioversion	 in	AF	
patients	undergoing	ECV	in	Helsinki	City	Hospitals.
2  | METHODS
This	study	included	consecutive	patients	undergoing	ECV	of	AF	or	
atrial	flutter	with	NOACs	(dabigatran,	rivaroxaban,	and	apixaban)	or	
warfarin	at	the	Haartman	and	Malmi	hospitals	of	Helsinki	city	from	
January	1,	2015,	to	December	31,	2016.	Patients	were	classified	as	
to whether or not they had or did not have ongoing anticoagulation 
therapy	at	the	time	of	AF	diagnosis.	Data	on	the	patient	characteris-
tics,	delays	to	cardioversion,	success	of	cardioversion,	anticoagula-
tion	 treatment,	acute	 (<30	days)	 complications	 (stroke	or	 systemic	
embolism,	 bleeding	 events,	 death	 or	 AF	 relapse),	 and	 reasons	 for	
changes	between	warfarin	and	NOACs	as	well	as	changes	between	
different	NOACs	 (<1	year)	were	collected	from	electronic	case-re-
port forms.
The	duration	of	AF	was	evaluated	from	the	documented	symp-
tom history in the patient's chart to the time of cardioversion. 
Delayed cardioversion was defined as postponed or canceled pri-
mary	ECV,	as	documented	in	the	medical	records	by	a	physician	or	
a nurse. Cardioversion was considered successful if sinus rhythm 
was restored and maintained for at least five minutes. The primary 
endpoint measure was stroke or systemic embolism. Patients were 
classified as having an embolic event if a thromboembolism was con-
firmed	by	computerized	tomography	or	magnetic	resonance	imaging	
or documented clinically by a physician. The primary safety outcome 
was any bleeding event reported in the patient's medical record 
during	a	30-day	follow-up.	Major	bleeding	events	were	defined	ac-
cording to the International Society of Thrombosis and Haemostasis 
criteria	(Schulman	&	Kearon,	2005).	Switches	between	NOACs	and	
VKAs	and	discontinuations	of	NOAC	therapy	were	analyzed	during	
a 12-month postcardioversion period.
2.1 | Statistical analysis
Continuous variables were tested for normality of distribution with 
the	Kolmogorov–Smirnov	test.	Normally	distributed	data	were	ana-
lyzed	 using	 Student's	 t	 test	 and	 presented	 as	 the	mean	 (standard	
deviation [SD]).	 Skewed	 continuous	 data	were	 analyzed	 using	 the	
Mann–Whitney	U	 test	 and	 presented	 as	 the	median	 (interquartile	
range	 [IQR]).	 Categorical	 variables	 were	 compared	 using	 the	 chi-
squared	test	or	Fisher's	exact	test	as	appropriate	and	presented	as	
numbers	(%).	A	p-value	<0.05	was	considered	statistically	significant.	
SPSS	Statistics	for	Windows,	version	24.0	(IBM	Corp.,	Armonk,	NY,	
USA),	was	used	for	the	statistical	analyses.
3  | RESULTS
3.1 | Study population
A	total	of	992	ECVs	were	performed	on	900	patients	(59.2%	men;	
mean	 age,	 68.0	 ±	 10.0).	 The	 patient	 characteristics	 of	 the	NOAC	
and	 warfarin	 groups	 are	 shown	 in	 Table	 1.	 The	 mean	 CHA2DS2-
VASc	 score	was	2.5	 (range	0–8),	 and	72.3%	of	 the	patients	had	 a	
CHA2DS2-VASc	 score	 ≥	 2,	 suggesting	 a	 high	 risk	 of	 stroke.	 The	
CHA2DS2-VASc	score	was	higher	in	the	warfarin	group	than	in	the	
NOAC	group	(p	<	.001).	The	index	episode	was	the	first	manifesta-
tion	of	AF	in	540	(60.0%)	patients.	Transthoracic	or	transesophageal	
echocardiograms	were	performed	for	639	(71.0%)	and	four	patients	
(0.4%),	respectively,	within	12	months	before	cardioversion.	These	
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revealed one intraventricular thrombus in a patient receiving dabi-
gatran 150 mg ×2. The thrombus was dissolved in a control prior to 
ECV.
3.2 | Anticoagulation
Five	hundred	ninety-six	(60.0%)	cardioversions	were	performed	on	
patients	taking	NOACs,	of	which	292	(49.0%)	were	on	rivaroxaban,	
162	(27.2%)	were	on	apixaban,	and	142	(23.8%)	were	on	dabigatran.	
Of	396	patients	 receiving	warfarin	 therapy,	6.1%	had	a	single	 INR	
value	below	2	during	the	three	weeks	preceding	ECV.	The	median	
number	of	INR	measurements	before	index	ECV	was	seven	(IQR	=	5).	
In	total,	99.2%	of	patients	using	VKAs	and	98.5%	of	patients	using	
NOACs	received	treatment	for	>	4	weeks	preceding	cardioversion.
In	patients	with	no	preexisting	oral	anticoagulation	(556	patients,	
61.8%),	the	mean	time	from	the	onset	of	anticoagulation	to	ECV	in	
NOAC-treated	patients	was	51	±	41	days,	and	the	median	time	was	
37	days	(IQR	=	21).	In	patients	who	started	warfarin	treatment,	the	
mean	time	to	cardioversion	was	68	±	42	days,	and	the	median	time	
was	53	days	(IQR	=	38)	(Figure	1).	ECV	was	postponed	more	often	
in	the	VKA	group	than	in	the	NOAC	group	(37.4%	versus	12.6%,	re-
spectively,	p	<	.001).	The	most	common	reason	for	visit	cancellation	
was	an	imbalance	of	warfarin	therapy	and	labile	INR	values	(Table	2).
The	 majority	 of	 cardioversions	 were	 successful	 (89.7%	 in	 the	
NOAC	 group	 and	 89.1%	 in	 the	warfarin	 group;	 p	 =	 .75).	 The	 suc-
cess	rate	was	94.3%	for	cardioversions	with	AF	duration	<	1	week,	
93.0%	for	cardioversions	with	AF	durations	of	1	week	to	1	month,	
and	 86.3%	 for	 cardioversions	with	 AF	 durations	 of	 over	 1	month	
(p	<	.001).	The	AF	recurrence	rates	during	the	one	30-day	follow-up	
period	in	the	NOAC	and	warfarin	groups	were	30.1%	(N	=	179/596)	
and	28.6%	(N	=	113/396),	respectively.
3.3 | Complications
During	 the	 30-day	 follow-up	 period	 after	 ECV,	 thromboembolic	
complications	occurred	 in	 four	patients	 (0.7%)	 in	 the	NOAC	group	
and	two	patients	(0.5%)	in	the	warfarin	group	(p	=	.25).	All	patients	
who	 experienced	 a	 stroke	 or	 TIA	 had	 adequate	 anticoagulation	
therapy	for	at	least	3	weeks	preceding	the	cardioversion,	and	both	
patients	in	the	warfarin	group	had	an	INR	value	>	2	when	thrombo-
embolic	complications	occurred.	Bleeding	events	that	were	clinically	
relevant	but	not	major	occurred	in	7	(1.8%)	patients	receiving	war-
farin	and	3	patients	 (0.5%)	receiving	NOACs	 (p	=	 .27).	The	patient	
characteristics of those with thromboembolic and bleeding compli-
cations are shown in Table 3.
3.4 | Anticoagulation after cardioversion
Among	 900	 patients,	 99	 patients	 (11.0%)	 experienced	 treatment	
changes	 during	 a	 12-month	 postcardioversion	 period:	 82	 patients	
switched	 from	 warfarin	 to	 NOAC,	 seven	 patients	 switched	 from	
NOAC	 to	warfarin,	 and	 three	 patients	 switched	between	NOACs.	
The	reasons	for	the	changes	between	OACs	are	shown	in	Table	4.	
One	hundred	fifty-seven	patients	 (17.4%)	stopped	their	anticoagu-
lation	 therapy	 four	weeks	after	ECV	because	of	 a	CHA2DS2-VASc	
score less than 2.
4  | DISCUSSION
The	results	of	this	real-life	study	showed	that	NOACs	were	associ-
ated with a shorter time to cardioversion and fewer postponements 
of	scheduled	ECVs	than	warfarin.	Furthermore,	our	experience	sup-
ports	the	view	that	NOACs	are	at	least	as	safe	and	effective	as	war-
farin	in	real-life	patients	undergoing	ECV.
The	 real-life	 data	 evaluating	 the	 safety	 and	 efficacy	 of	 ECV	
in	patients	receiving	NOACs	are	sparse	 (Frederiksen	et	al.,	2018;	
Pallisgaard	 et	 al.,	 2015).	 In	 line	 with	 previous	 studies	 (Cappato	
et	 al.,	 2014;	 Goette	 et	 al.,	 2016),	 the	 precardioversion	 use	 of	
NOACs	enabled	faster	progression	to	ECV	with	fewer	cancelations	
TA B L E  1   Patient characteristics
Patients characteristics
NOAC
N = 596 
(60.0%)
Warfarin
N = 396 
(40.0%)
p-
value
Age	(mean	±	SD) 67.1	(±10.2) 68.9	(±9.5) .004
CHA2DS2-VASc	score 2.2	(±1.5) 2.7	(±1.6) <.001
HAS-BLED	score 0.8	(±0.7) 1.1	(±0.8) <.001
Congestive heart failure 61	(11.3) 50	(14.0) .27
Hypertension 315	(58.1) 257	(71.8) <.001
Diabetes mellitusa  97	(17.9) 76	(21.2) .52
History	of	stroke	or	TIA 13	(2.4) 24	(6.7) .29
Liver	cirrhosisb  0	(0.0) 2	(0.6) .08
Renal failurec  13	(2.4) 26	(7.3) <.001
Alcohol	overused  47	(8.7) 34	(9.5) .81
Previous myocardial 
infarction
35	(6.5) 39	(10.9) .006
Bleeding	tendencye  4	(0.7) 8	(2.0) .59
Known	thrombophilia 7	(1.3) 7	(2.0) .36
Antiarrhythmic	therapyf 	
precardioversion
61	(10.2) 36	(9.1)  
Antiarrhythmic	therapy	
postcardioversion
95	(15.9) 63	(15.9)  
Abbreviation:	TIA,	transient	ischemic	attack.
aKnown	diagnosis	or	fasting	glucose	repeatedly	over	7.	
bKnown	diagnosis	or	Bil	>	×2	ULN	(upper	limit	of	normal)	or	ASAT/
ALAT	>	×3	ULN.	
cCreatinine	>	140	μmol/L	or	eGFR	<	40	ml/min.	
dWomen	>	14	portions/week	and	men	>	23	portions/week.	
eHemoglobin	<	120	mmol/L,	thrombocytes	<	150	10f/L,	or	previous	
significant bleeding event. 
fClasses	I-IV	according	to	Vaughan	Williams	classification	plus	digoxin.	
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of	planned	ECVs	than	warfarin.	The	median	time	to	the	index	ECV	
was	37	days,	which	was	shorter	than	that	of	patients	treated	with	
warfarin	 in	previous	 studies	 (Lehto	&	Kala,	 2003).	 The	 tendency	
toward a shorter time to cardioversion in real-life patients was 
also	noted	in	two	Danish	studies,	where	in	one	study,	the	waiting	
time	for	cardioversion	in	the	NOAC	group	was	28	days,	and	in	the	
other	study,	80%	of	 the	cardioversions	 in	 the	NOAC	group	were	
performed	 within	 28	 days	 (Frederiksen	 et	 al.,	 2018;	 Pallisgaard	
et	al.,	2015).	In	our	study,	the	median	time	to	index	ECV	for	NOAC-
treated	patients	was	higher	than	the	median	times	of	those	studies,	
yet cardioversion was deliberately postponed for only 75 patients 
(12.6%).	This	finding	indicates	that	there	is	a	need	for	improvement	
in	our	system	to	achieve	cardioversion	within	3–4	weeks	in	AF	pa-
tients	treated	with	NOAC.	Currently,	the	advantage	of	the	shorter	
necessary	time	before	ECV	with	NOACs	is	not	fully	applied	in	our	
system.	Moreover,	TOEs	were	performed	for	only	4	(0.4%)	patients	
before	ECV.	Its	use	may	shorten	the	waiting	times	for	elective	car-
dioversion also in patients having warfarin and should therefore be 
used more often in our system.
There are limited data on the reasons for the delay to cardio-
version.	 In	 this	 study,	 patients	 receiving	warfarin	had	 significantly	
more	 frequent	 delays	 to	 ECV	 than	patients	 receiving	NOACs.	 For	
warfarin-treated	patients,	the	main	reasons	for	ECV	postponements	
were	labile	INR	values.	A	major	disadvantage	of	warfarin	is	its	nar-
row	 therapeutic	window,	 causing	 easily	 subtherapeutic	 INR	 levels	
and	delays	in	ECV.	Earlier	reports	(Itainen	et	al.,	2018;	Lehto	&	Kala,	
2003)	have	suggested	that	a	shorter	duration	from	the	onset	of	AF	
to	 cardioversion	 may	 decrease	 the	 risk	 for	 AF	 recurrence.	 In	 our	
study,	the	AF	recurrence	rate	was	approximately	30%,	with	no	dif-
ference	between	the	two	groups	and,	in	contrast	to	previous	stud-
ies,	no	correlation	between	a	short	AF	duration	and	the	recurrence	
rate.	Only	15.9%	of	patients	were	treated	with	antiarrhythmic	drugs	
after	ECV,	which	may	have	resulted	in	relatively	high	recurrence	rate.	
However,	the	success	rate	was	significantly	higher	in	cardioversion	
with	a	shorter	AF	duration	and	in	cardioversions	with	an	AF	dura-
tion	<	30	days,	and	the	success	rate	was	higher	than	those	of	earlier	
studies	(Hellman	et	al.,	2018).
In	 line	 with	 previous	 studies	 (Lehto	 &	 Kala,	 2003;	 Ruff	
et	 al.,	 2014),	 the	 incidence	 of	 thromboembolic	 and	 bleeding	 com-
plications	in	real-life	patients	undergoing	ECV	was	low	in	the	pres-
ent study. Thromboembolic complications occurred in two patients 
(0.5%)	in	the	warfarin	group	and	four	patients	(0.7%)	in	the	NOAC	
F I G U R E  1   Duration of anticoagulation 
before elective cardioversion in patients 
without	preexisting	anticoagulation	
therapy.	The	vertical	line	through	the	box	
represents the median. The upper ends 
of	the	boxes	represent	the	upper	quartile	
(3rd	quartile),	and	the	lower	ends	of	the	
boxes	represents	the	lower	quartile	(1st	
quartile).	The	top	whisker	extends	to	the	
maximum	value,	and	the	lower	whisker	
extends	to	the	minimum	value
0
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TA B L E  2  Number	(percentage)	and	reasons	for	postponing	the	
index	cardioversion
Reason
NOAC
N (%)
Warfarin
N (%)
p-
value
Delay 75	(12.6) 148	(37.4) <.001
Labile	INR	values	
(warfarin)
0	(0.0) 121	(81.8)  
Noncompliance	
(NOAC)
15	(20.0) 0	(0.0)  
Thromboembolic 
or bleeding 
complications
5	(6.7) 1	(0.7)  
Infection 5	(6.7) 1	(0.7)  
Heart failure 9	(12.0) 13	(8.9)  
Hyper- or 
hypothyroidism
3	(4.0) 2	(1.4)  
Travel 10	(13.3) 0	(0.0)  
Surgery 4	(5.3) 0	(0.0)  
Hypokalemia 1	(1.3) 1	(0.7)  
Referral problems 8	(10.7) 2	(1.4)  
Othera  10	(13.3) 4	(2.7)  
Unknown	delay 6	(8.0) 3	(2.0)  
Abbreviation:	INR,	international	normalized	ratio.
aMedication	dosage	(NOAC)	that	was	too	low,	diagnostic	workup	
pending,	dabigatran	kept	in	administration	aids	such	as	dosette	boxes	
prior	to	ECV.	
     |  5 of 7ITÄINEN-STRÖMBERG ET al.
group.	The	CHA2DS2-VASc	score	was	higher	in	the	warfarin	group	
than	in	the	NOAC	group,	but	the	number	of	thromboembolic	events	
was so low that possible differences between the warfarin and 
NOAC	groups	could	not	be	determined.	No	major	or	fatal	bleeding	
events were documented during the follow-up.
In	 11.0%	 of	 the	 patients,	 the	 anticoagulation	 treatment	 was	
changed	during	the	one-year	 follow-up	after	 the	 index	ECV.	The	
rate	for	switches	between	OACs	was	 lower	than	those	of	earlier	
studies	 (Beyer-Westendorf	et	al.,	2015;	Hellfritzsch	et	al.,	2017),	
which indicate that more emphasis was placed on achieving high 
treatment	persistence	in	AF	patients	with	scheduled	ECVs.	Most	
of	the	changes	were	from	warfarin	to	NOACs,	and	the	most	com-
mon	reasons	for	treatment	changes	were	labile	INR	values	and	pa-
tient	preference.	Therefore,	patients	who	were	prescribed	NOACs	
had	 a	 higher	 drug	 persistence	 rate	 within	 one	 year	 after	 ECV	
than patients who were prescribed warfarin. Thromboembolic or 
bleeding complications were rarely the reasons for changing be-
tween	OACs.
4.1 | Limitations
A	retrospective	analysis	does	not	allow	characterization	of	the	study	
cohort as precisely as a prospective trial. We were dependent on 
the data recorded by the physicians who performed the cardiover-
sions	and	who	were	responsible	for	follow-up.	Moreover,	the	clini-
cal characteristics of the two study groups were different. In the 
warfarin	group,	patients	were	older	and	had	more	often	comorbidi-
ties,	for	example,	hypertension	and	renal	failure,	that	could	explain	
a	lower	drug	adherence	and	a	higher	complication	rate.	Additionally,	
the onset of arrhythmia was based on the beginning of the patient's 
symptoms	 in	 the	medical	 records,	making	the	exact	onset	difficult	
to	determine.	Also,	echocardiography	was	not	performed	 in	every	
patient in the real-life setting and we could not collect comprehen-
sive	data	on,	for	example,	 left	atrial	size	which	might	affect	AF	re-
currence	 rate.	Another	 limitation	of	our	 study	 is	 the	nonexistence	
of	a	laboratory	test	to	confirm	patient	adherence	to	NOAC	therapy,	
though	all	patients	scheduled	for	cardioversion	of	AF	are	informed	
about	the	importance	of	adherence.	Lastly,	due	to	the	low	number	
of	complications,	the	power	of	the	study	does	not	allow	for	a	rea-
sonable	estimation	of	differences	between	the	NOAC	and	warfarin	
groups.
TA B L E  3   Characteristics of the patients with thromboembolic or bleeding complications
Patient Complication Day Age Sex
CHA2DS2-VASc 
score
HAS-BLED 
score Anticoagulation
1 Stroke 4 64 Female 1 0 Rivaroxaban	20	mgx1
2 Stroke 2 88 Female 3 1 Warfarin
3 TIA 9 75 Female 3 1 Warfarin
4 TIA 14 61 Male 2 0 Apixaban	5	mgx2
5 TIA 21 78 Male 3 2 Rivaroxaban	15	mgx1
6 Central retinal vein 
thrombosis
24 79 Male 3 1 Rivaroxaban	20	mgx1
1 GI-bleeding 30 80 Female 3 2 Warfarin
2 GI-bleeding 14 60 Male 1 0 Warfarin
3 GI-bleeding 28 74 Female 5 2 Warfarin
4 GI-bleeding 13 78 Female 3 2 Warfarin
5 GI-bleeding 6 68 Male 7 3 Warfarin
6 GI-bleeding 2 86 Male 5 2 Rivaroxaban	15	mgx1
7 Nosebleed 18 72 Male 1 1 Rivaroxaban	15	mgx1
8 Postmenopausal 
bleeding
12 79 Female 3 1 Dabigatran	150	mgx2
9 Bleeding	unspecified 30 84 Male 4 2 Warfarin
10 Bleeding	unspecified 24 71 Male 4 3 Warfarin
Abbreviations:	GI,	gastrointestinal;	TIA,	transient	ischemic	attack.
TA B L E  4  Reason	for	change	in	99	patients	(11.0%)	who	changed	
their anticoagulation treatment during the study
Reason No. (%)
Thromboembolic or bleeding complication 8	(8.1)
Patient preference 26	(26.3)
Labile	INR	values 30	(30.3)
Side effects 4	(4.0)
Economic reasons 3	(3.0)
Unknown 28	(28.3)
Abbreviation:	INR,	international	normalized	ratio.
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5  | CONCLUSION
The	use	of	NOACs	seems	to	be	as	safe	and	effective	as	that	of	war-
farin in the real-world setting of elective cardioversion. Patients 
receiving warfarin have significantly more delays in treatment than 
patients	receiving	NOACs,	prolonging	the	time	to	ECV.	Furthermore,	
our	results	indicate	better	adherence	with	NOACs	than	with	warfa-
rin in the daily care of patients.
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